依普利酮属于哪一类降压药物？

Which class of antihypertensive drugs does it belong to? Eplerenone is a new type of selective aldosterone receptor antagonist, its English name is Inspra. It was approved for clinical use by the State Food and Drug Administration in 2002. The pure product is white or off-white crystals. Eplerenone is a good medicine for the treatment of hypertension. It is also effective in the treatment of myocardial ischemia and chronic myocardial insufficiency. It has a protective effect on the liver, heart, and kidneys without damaging the organs.

The initial dose of eplerenone for the treatment of congestive heart failure is 25 mg orally once daily; the dose can be increased to the target dose within four weeks as tolerated by the patient. The target dose is 50 mg orally once daily.

When treating adult patients with hypertension, eplerenone (Inspra) can be used alone or in combination with other antihypertensive drugs. It is administered orally. The initial dose is 50 mg, once a day; the maintenance dose is 50 mg, 1-2 times a day. The maximum dose is 100 mg/day and patients should not overdose. Typically, significant blood pressure lowering effects occur within four weeks of taking eplerenone. Patients whose blood pressure responds inadequately to the initial dose may be increased to 50 mg twice daily.

Studies have shown that for severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. Combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve patients' quality of life and reduce mortality in severe heart failure and myocardial infarction.

(Inspra) provides patients with a new solution in the treatment of high blood pressure, which can effectively reduce the patient's risk of disease. If you have other questions, you can consult the medical companion travel service for answers.

Recommended related hot articles: /newsDetail/72934.html